Literature DB >> 16492112

Differential involvement of enkephalins in analgesic tolerance, locomotor sensitization, and conditioned place preference induced by morphine.

Paul Marquez1, Ramkumarie Baliram, Nagaraju Gajawada, Theodore C Friedman, Kabirullah Lutfy.   

Abstract

In this study, the authors investigated the role of enkephalins in morphine-induced conditioned place preference, locomotor sensitization, and analgesic tolerance. Both preproenkephalin wild type (ppENK [+/+]) and knockout (ppENK [-/-]) mice showed similar preference for the morphine-paired chamber over the vehicle-paired chamber, indicating morphine induced comparable conditioned place preference in ppENK (+/+) and ppENK (-/-) mice. Sensitization developed to the motor stimulatory action of morphine after its repeated administration, but the magnitude of this response was not altered in ppENK (-/-) mice. However, as shown previously, ppENK (-/-) mice displayed blunted morphine analgesic tolerance. Taken together, the results suggest that enkephalins may be important for the development of analgesic tolerance but not for conditioned place preference or behavioral sensitization induced by morphine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492112      PMCID: PMC2268890          DOI: 10.1037/0735-7044.120.1.10

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  38 in total

Review 1.  Incentive-sensitization and addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

2.  Selective reward deficit in mice lacking beta-endorphin and enkephalin.

Authors:  Michael D Hayward; John E Pintar; Malcolm J Low
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 3.  Drugs of abuse: anatomy, pharmacology and function of reward pathways.

Authors:  G F Koob
Journal:  Trends Pharmacol Sci       Date:  1992-05       Impact factor: 14.819

4.  GABA and enkephalin projection from the nucleus accumbens and ventral pallidum to the ventral tegmental area.

Authors:  P W Kalivas; L Churchill; M A Klitenick
Journal:  Neuroscience       Date:  1993-12       Impact factor: 3.590

Review 5.  A psychomotor stimulant theory of addiction.

Authors:  R A Wise; M A Bozarth
Journal:  Psychol Rev       Date:  1987-10       Impact factor: 8.934

6.  Regional reward differences within the ventral pallidum are revealed by microinjections of a mu opiate receptor agonist.

Authors:  P I Johnson; J R Stellar; A D Paul
Journal:  Neuropharmacology       Date:  1993-12       Impact factor: 5.250

7.  Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya.

Authors:  P W Kalivas; P Duffy
Journal:  J Neurosci       Date:  1993-01       Impact factor: 6.167

8.  Microdialysis reveals a morphine-induced increase in pallidal opioid peptide release.

Authors:  M F Olive; M Bertolucci; C J Evans; N T Maidment
Journal:  Neuroreport       Date:  1995-05-30       Impact factor: 1.837

9.  Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals.

Authors:  P W Kalivas; P Duffy
Journal:  J Neurosci       Date:  1993-01       Impact factor: 6.167

10.  Evidence for the coexistence of glutamate decarboxylase and Met-enkephalin immunoreactivities in axon terminals of rat ventral pallidum.

Authors:  D S Zahm; L Zaborszky; V E Alones; L Heimer
Journal:  Brain Res       Date:  1985-01-28       Impact factor: 3.252

View more
  14 in total

1.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  The role of mu opioid receptors in psychomotor stimulation and conditioned place preference induced by morphine-6-glucuronide.

Authors:  Alexander T Nguyen; Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Eur J Pharmacol       Date:  2012-02-21       Impact factor: 4.432

4.  Gene expression profiling following short-term and long-term morphine exposure in mice uncovers genes involved in food intake.

Authors:  A Anghel; C A M Jamieson; X Ren; J Young; R Porche; E Ozigbo; D E Ghods; M L Lee; Y Liu; K Lutfy; T C Friedman
Journal:  Neuroscience       Date:  2010-02-06       Impact factor: 3.590

Review 5.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

6.  Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence.

Authors:  K Lutfy; D Parikh; D L Lee; Y Liu; M G Ferrini; A Hamid; T C Friedman
Journal:  Neuroscience       Date:  2016-05-18       Impact factor: 3.590

7.  The role of beta-endorphin in the acute motor stimulatory and rewarding actions of cocaine in mice.

Authors:  Paul Marquez; Ramkumarie Baliram; Ibrahim Dabaja; Nagaraju Gajawada; Kabirullah Lutfy
Journal:  Psychopharmacology (Berl)       Date:  2008-01-06       Impact factor: 4.530

8.  The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference.

Authors:  Paul Marquez; Ramkumarie Baliram; Brigitte L Kieffer; Kabirullah Lutfy
Journal:  Neuropharmacology       Date:  2007-01-20       Impact factor: 5.250

9.  The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine.

Authors:  P Marquez; J Borse; A T Nguyen; A Hamid; K Lutfy
Journal:  Neuroscience       Date:  2008-06-19       Impact factor: 3.590

10.  The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine.

Authors:  Paul Marquez; Alexander T Nguyen; Abdul Hamid; Kabirullah Lutfy
Journal:  Neuropharmacology       Date:  2007-11-17       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.